accountundergoing knee surgery. Patients in that trial received 30 milligrams of enoxaparin, dosed twice a day. Bristol-Myers and Pfizer, following the failed U.S. trial, have not asked U.S. regulators to approve Eliquis for orthopedic patients, or signaled an...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to UPDATE 1-Bristol, Pfizer anti-clot pill wins EU approval
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account